Purple Biotech (PPBT) Net Cash Flow (2017 - 2026)

Purple Biotech (PPBT) has 10 years of Net Cash Flow data on file, last reported at -$3.1 million in Q1 2026.

• On a quarterly basis, Net Cash Flow fell 94.07% year-over-year to -$3.1 million in Q1 2026; TTM through Mar 2026 was -$213000.0, a 94.93% increase from a year earlier, with the FY2025 full-year figure at $1.3 million, up 118.48% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$3.1 million, down from -$874000.0 in the prior quarter.
• Over the last five years, Net Cash Flow for PPBT reached as high as $12.7 million in Q1 2022 and fell as low as -$9.4 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$306882.4 across 5 years, with a median of -$1.1 million in 2024.
• On a YoY basis, Net Cash Flow climbed as much as 1565.66% in 2022 and fell as far as 3228.0% in 2022.
• Year by year, Net Cash Flow stood at $3.9 million in 2022, then plunged by 117.09% to -$662000.0 in 2023, then jumped by 396.53% to $2.0 million in 2024, then plunged by 144.52% to -$874000.0 in 2025, then slumped by 259.27% to -$3.1 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$3.1 million in Q1 2026, -$874000.0 in Q4 2025, and $4.9 million in Q3 2025.